← Back to Search

Drug Therapy for Anxiety

N/A
Recruiting
Research Sponsored by University of Manitoba
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males and females who are between 18 and 40 years of age
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up derived from eegs recorded for 30-45 mins
Awards & highlights

Study Summary

This trial will attempt to identify if there is a relationship between vestibular signals and anxiety by studying the effects of two different drugs known to reduce the theta rhythm.

Who is the study for?
This trial is for men and women aged 18-40 without a history of substance use disorders, neurological illnesses, major hearing loss, or severe allergies. They shouldn't be pregnant, left-handed, colorblind, have had psychological treatment or taken psychiatric drugs in the past year.Check my eligibility
What is being tested?
The study tests if non-invasive EVestG technology can detect anxiety by measuring hippocampal theta rhythms from the ear canal. Participants will receive Buspirone or Triazolam (both known to reduce theta rhythm) versus a placebo in a double-blind setup.See study design
What are the potential side effects?
Potential side effects include dizziness, nausea, headache from Buspirone; drowsiness, memory issues from Triazolam; and no active side effects expected from the placebo.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 40 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~derived from eegs recorded for 30-45 mins
This trial's timeline: 3 weeks for screening, Varies for treatment, and derived from eegs recorded for 30-45 mins for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
4-12 Hz modulation
EEG power spectrum
Secondary outcome measures
Signal correlations

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: TriazolamExperimental Treatment1 Intervention
Participants will receive triazolam 0.25 mg prior to experiments.
Group II: BuspironeExperimental Treatment1 Intervention
Participants will receive buspirone 10 mg prior to experiments.
Group III: PlaceboPlacebo Group1 Intervention
Participants will receive a placebo prior to experiments.

Find a Location

Who is running the clinical trial?

University of ManitobaLead Sponsor
593 Previous Clinical Trials
199,346 Total Patients Enrolled
8 Trials studying Anxiety
562 Patients Enrolled for Anxiety

Media Library

Triazolam 0.25 MG Oral Tablet Clinical Trial Eligibility Overview. Trial Name: NCT03954483 — N/A
Anxiety Research Study Groups: Triazolam, Buspirone, Placebo
Anxiety Clinical Trial 2023: Triazolam 0.25 MG Oral Tablet Highlights & Side Effects. Trial Name: NCT03954483 — N/A
Triazolam 0.25 MG Oral Tablet 2023 Treatment Timeline for Medical Study. Trial Name: NCT03954483 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have enrolled in this trial thus far?

"At this time, no further participants are being accepted. This research project was initially posted on January 1st 2023 and had its last update on October 31st 2022. If interested in other studies, there is a total of 374 trials recruiting patients with anxiety as well as 9 clinical studies requiring individuals for the administration of Triazolam 0.25 MG Oral Tablet."

Answered by AI

Has the efficacy of Triazolam 0.25 MG Oral Tablet been explored in other research studies?

"At the current moment, there are 9 clinical trials that utilize Triazolam 0.25 MG Oral Tablets with none of them in Phase 3 status. Most locations for these studies are located in Tianjin but overall, nine sites across multiple regions have active research centers focused on this drug."

Answered by AI

What indications would necessitate a prescription of Triazolam 0.25 MG Oral Tablet?

"Triazolam 0.25 MG Oral Tablet is a medication primarily used for treating insomnia, although it can also be employed to provide sedation during therapy and reduce symptoms of anxiety."

Answered by AI

Is enrollment open for this experiment currently?

"The information posted on clinicaltrials.gov suggests that this medical investigation is not currently seeking participants, as the last update was made October 31st 2022. However, 383 other studies are actively enrolling patients right now."

Answered by AI

Does this research endeavor allow for individuals aged 85 or above to participate?

"This clinical trial is recruiting participants with an age range of 18 to 40 years old."

Answered by AI

Do I meet the qualifications for taking part in this investigation?

"This study is recruiting a cohort of 42 anxious individuals aged 18 and 40. To be eligible, participants must also meet the following requirements: both sexes between 18 to 40 years old."

Answered by AI
~28 spots leftby Sep 2025